About MicuRx
Our company
Our Team
Vision & mission
History
Contact Us
Scientific research
Antibiotic Resistance
Kidney Disease
MicuRx R&D
Publications
Pipeline
Newsroom
Corporate news
Careers
Contact Us
中
Scientific research
Home
Publications
Antibiotic Resistance
Kidney Disease
MicuRx R&D
Publications
A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo
Antimicrobial Agents and Chemotherapy / 2022
View Publication
Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies
ACS Med. Chem. Lett. / 2022
View Publication
Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections
Antimicrobial Agents and Chemotherapy / 2022
View Publication
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections
Journal of Antimicrobial Chemotherapy / 2022
View Publication
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
Antimicrobial Agents and Chemotherapy / 2021
View Publication
Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development
Antimicrobial Agents and Chemotherapy / 2021
View Publication
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity
Chem Res Toxicol / 2021
View Publication
Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens
Antimicrobial Agents and Chemotherapy / 2020
View Publication
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Antimicrob Agents Chemother / 2020
View Publication
Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
Antimicrob Agents Chemother / 2020
View Publication
Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients
Clinical Therapeutics / 2020
View Publication
Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
Clinical Therapeutics / 2019
View Publication
1
2
>
Close